Abstract 32P
Background
Worldwide breast cancer morbidity and mortality was still positioned in the top. Epidemiological data for breast cancer in Bali was not available although is essential for planning health measures. This study aimed to summarise the demographics of breast cancer subjects in Sanglah Genral Hospital from 2012-2019 and emphasize variables that related.
Methods
This is a descriptive study, collecting all breast cancer subjects data from January 2012 to 2019. All data from the cancer registry were analyzed and tabulated. Data were described as count and percentages. Reasoning analysis was done by looking at the counts from year to year. Information for counting age standardized rate was taken in national census data of population in Bali. Literature review if articles were also screened for the filtering out of the data regarding epidemiology of breast cancer in worldwide for comparison.
Results
A total of 1627 cases from 2012 to 2019 were included in this study for analysis. The incidence of breast cancer increase from 187 cases to 364 cases from 2013 to 2016. The age-standardized incidence rate was 84.33 per 100.000 women Balinese population. Most cases were found in advanced stages, stage IIIB (29.38%) and stage IV (22.56%). The most common tumor status found was T4 (49.78%), N1 (41.49%), and 22.5% were found to have metastasis. Lung metastasis dominated all the metastasis cases with the rate of 42.35%. Majority of histopathology subtypes in breast cancer subjects were invasive carcinoma of non special type (NST) (78.8%), followed by invasive lobular carcinoma (12.4%). From 1627 subjects, only 1160 (71.3%) had subtype tested, with luminal B subtype dominated the cases (36.5%).
Conclusions
Geographical and phenotypical variations differ from breast cancer subject epidemiology. Thus, statistical data should be done in each region for a better diagnosis and treatment care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract